JPH09511991A - ロバプラチナ三水和物 - Google Patents
ロバプラチナ三水和物Info
- Publication number
- JPH09511991A JPH09511991A JP7526663A JP52666395A JPH09511991A JP H09511991 A JPH09511991 A JP H09511991A JP 7526663 A JP7526663 A JP 7526663A JP 52666395 A JP52666395 A JP 52666395A JP H09511991 A JPH09511991 A JP H09511991A
- Authority
- JP
- Japan
- Prior art keywords
- platinum
- trihydrate
- donkey
- cis
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283074 Equus asinus Species 0.000 title claims abstract description 16
- YPUBCBDXROWIBU-UHFFFAOYSA-N platinum trihydrate Chemical compound [Pt].O.O.O YPUBCBDXROWIBU-UHFFFAOYSA-N 0.000 title claims abstract description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 150000004684 trihydrates Chemical group 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- 239000012535 impurity Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000003109 Karl Fischer titration Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- ZBLACDIKXKCJGF-UHFFFAOYSA-N [2-(aminomethyl)cyclobutyl]methanamine Chemical compound NCC1CCC1CN ZBLACDIKXKCJGF-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- GSAGSFUIGAWHNR-UHFFFAOYSA-N cyclobutylmethanamine;platinum Chemical compound [Pt].NCC1CCC1 GSAGSFUIGAWHNR-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- WNADCRRBSCXKGU-UHFFFAOYSA-N platinum trihydrate Chemical class O.O.O.[Pt].[Pt] WNADCRRBSCXKGU-UHFFFAOYSA-N 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.次の式: のシス−[トランス−1,2−シクロブタンビス(メチルアミン)−N,N’] −[(2S)−ラクタト−O1,O2)−白金(II)三水和物(ロバプラチナ) 。 2.ロバプラチナ三水和物の製法において、ハロゲンリガンドの交換反応及び その後処理を水性媒体中で実施することにより、シス−[トランス−1,2−シ クロブタンビス(メチルアミン)−N,N’]−ジハロゲノ白金(II)を、シ ス−[トランス−1,2−シクロブタンビス(メチルアミン)−N,N’]−[ (2S)−ラクタト−O1,O2)−白金(II)三水和物に変換させることを特 徴とする、ロバプラチナ三水和物の製法。 3.シス−[トランス−1,2−シクロブタンビス(メチルアミン)−N,N ’]−[(2S)−ラクタト−O1,O2)−白金(II)三水和物及び慣用の賦 形剤、希釈剤及び/又は添加剤を有する製剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4415263A DE4415263C1 (de) | 1994-04-15 | 1994-04-15 | Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung |
| DE4415263.9 | 1994-04-15 | ||
| PCT/EP1995/001214 WO1995028407A1 (de) | 1994-04-15 | 1995-03-31 | Lobaplatin-trihydrat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09511991A true JPH09511991A (ja) | 1997-12-02 |
| JP3579423B2 JP3579423B2 (ja) | 2004-10-20 |
Family
ID=6516957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52666395A Expired - Fee Related JP3579423B2 (ja) | 1994-04-15 | 1995-03-31 | ロバプラチナ三水和物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5747534A (ja) |
| EP (1) | EP0755399B1 (ja) |
| JP (1) | JP3579423B2 (ja) |
| CN (1) | CN1041094C (ja) |
| AT (1) | ATE185142T1 (ja) |
| AU (1) | AU2256195A (ja) |
| DE (2) | DE4415263C1 (ja) |
| DK (1) | DK0755399T3 (ja) |
| ES (1) | ES2138199T3 (ja) |
| GR (1) | GR3032061T3 (ja) |
| IL (1) | IL113360A (ja) |
| TW (1) | TW367329B (ja) |
| WO (1) | WO1995028407A1 (ja) |
| ZA (1) | ZA953095B (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017517572A (ja) * | 2014-06-20 | 2017-06-29 | 貴州益佰制葯股▲ふん▼有限公司 | ロバプラチン結晶体、調製方法及び薬物応用 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100314720B1 (ko) * | 1999-03-26 | 2001-11-26 | 박호군 | 포스파젠 삼합체에 도입된 백금 착물, 그의 제조방법 및 그를 유효성분으로 하는 항암제 |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| CN102020679B (zh) * | 2010-11-24 | 2013-12-25 | 贵州益佰制药股份有限公司 | 一种以草酸盐制备洛铂三水合物的方法 |
| CN103467528B (zh) * | 2013-08-21 | 2016-06-08 | 江苏奥赛康药业股份有限公司 | 一种洛铂的制备方法 |
| IL296691B2 (en) | 2014-04-25 | 2023-11-01 | 2Seventy Bio Inc | MND promoter chimeric antigen receptors |
| EP3738597A1 (en) | 2014-04-25 | 2020-11-18 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| CN106793780B (zh) | 2014-06-06 | 2020-05-26 | 蓝鸟生物公司 | 改善的t细胞组合物 |
| CN105218587B (zh) * | 2014-06-20 | 2018-08-14 | 贵州益佰制药股份有限公司 | 一种洛铂晶体、制备方法及药物应用 |
| CN105330702B (zh) * | 2014-06-20 | 2018-08-14 | 贵州益佰制药股份有限公司 | 一种洛铂晶体、制备方法及药物应用 |
| CN105198932B (zh) * | 2014-06-20 | 2018-09-21 | 贵州益佰制药股份有限公司 | 洛铂二水合物、制备方法及药物应用 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| CN111721843B (zh) * | 2019-03-19 | 2022-05-17 | 海南长安国际制药有限公司 | 与洛铂有关物质的检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7807334A (nl) * | 1978-07-06 | 1980-01-08 | Tno | Platina-diaminecomplexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een genees- middel met toepassing van een dergelijk platina-dia- minecomplex voor de behandeling van kanker, alsmede al- dus verkregen gevormd geneesmiddel. |
| SU1186617A1 (ru) * | 1980-01-03 | 1985-10-23 | Нидерландзе Сентрале Организати Фор Тегепаст-Натурветеншаппелийк Ондерцоек (Фирма) | Платино ( @ )-диаминовые комплексы,про вл ющие противоопухолевую активность |
| NL181434C (nl) * | 1980-01-03 | 1987-08-17 | Tno | Platina(iv)-diamine-complexen, alsmede hun bereiding en toepassing. |
| US4912100A (en) * | 1986-10-15 | 1990-03-27 | Toray Industries, Inc. | Platinum complex, process for preparing same and antitumor agent |
| DE3843571A1 (de) * | 1988-01-09 | 1989-07-20 | Asta Pharma Ag | 1,2-bis(aminomethyl)cyclobutan-platin-komplexe |
| JPH02275891A (ja) * | 1988-12-29 | 1990-11-09 | Tsumura & Co | 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤 |
| DE4115559A1 (de) * | 1990-05-15 | 1991-11-21 | Deutsches Krebsforsch | Antitumormittel mit verminderter toxizitaet auf der basis von cytostatika und xanthogenaten |
-
1994
- 1994-04-15 DE DE4415263A patent/DE4415263C1/de not_active Expired - Fee Related
- 1994-06-20 CN CN94106670A patent/CN1041094C/zh not_active Expired - Lifetime
-
1995
- 1995-03-31 JP JP52666395A patent/JP3579423B2/ja not_active Expired - Fee Related
- 1995-03-31 DE DE59506958T patent/DE59506958D1/de not_active Expired - Fee Related
- 1995-03-31 EP EP95915838A patent/EP0755399B1/de not_active Expired - Lifetime
- 1995-03-31 ES ES95915838T patent/ES2138199T3/es not_active Expired - Lifetime
- 1995-03-31 DK DK95915838T patent/DK0755399T3/da active
- 1995-03-31 AU AU22561/95A patent/AU2256195A/en not_active Abandoned
- 1995-03-31 AT AT95915838T patent/ATE185142T1/de not_active IP Right Cessation
- 1995-03-31 WO PCT/EP1995/001214 patent/WO1995028407A1/de not_active Ceased
- 1995-04-13 ZA ZA953095A patent/ZA953095B/xx unknown
- 1995-04-13 IL IL11336095A patent/IL113360A/xx not_active IP Right Cessation
- 1995-04-14 TW TW084103672A patent/TW367329B/zh not_active IP Right Cessation
-
1996
- 1996-09-16 US US08/714,456 patent/US5747534A/en not_active Expired - Lifetime
-
1999
- 1999-12-07 GR GR990403150T patent/GR3032061T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017517572A (ja) * | 2014-06-20 | 2017-06-29 | 貴州益佰制葯股▲ふん▼有限公司 | ロバプラチン結晶体、調製方法及び薬物応用 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0755399T3 (da) | 2000-03-27 |
| ZA953095B (en) | 1996-01-05 |
| CN1041094C (zh) | 1998-12-09 |
| WO1995028407A1 (de) | 1995-10-26 |
| ES2138199T3 (es) | 2000-01-01 |
| IL113360A0 (en) | 1995-07-31 |
| US5747534A (en) | 1998-05-05 |
| EP0755399B1 (de) | 1999-09-29 |
| DE4415263C1 (de) | 1995-11-30 |
| ATE185142T1 (de) | 1999-10-15 |
| GR3032061T3 (en) | 2000-03-31 |
| EP0755399A1 (de) | 1997-01-29 |
| JP3579423B2 (ja) | 2004-10-20 |
| DE59506958D1 (de) | 1999-11-04 |
| IL113360A (en) | 1999-09-22 |
| AU2256195A (en) | 1995-11-10 |
| TW367329B (en) | 1999-08-21 |
| CN1120046A (zh) | 1996-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4256652A (en) | Platinum complex | |
| JP3579423B2 (ja) | ロバプラチナ三水和物 | |
| US5480875A (en) | Crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative | |
| CA1258865A (en) | Platinum complexes | |
| EP0136012B1 (en) | Cytostatic platinum complexes | |
| US4452812A (en) | Organic complex of platinum, its preparation and its use for treating malignant tumors | |
| US20230117777A1 (en) | Methylation of mcl-1 compounds | |
| HU185951B (en) | Method for producing co-ordination compounds of platinum | |
| JPWO1994000462A1 (ja) | ヘテロ環ビス(フォスフォン酸)誘導体1水和物の新規結晶 | |
| WO2023201707A1 (en) | Process for chemical synthesis of ergothioneine and methods of use | |
| EP0327709A2 (en) | Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use | |
| RU2648990C1 (ru) | Кристаллы лобаплатина, способы получения и применения в фармацевтике | |
| JPH0469157B2 (ja) | ||
| CN111875530A (zh) | 一种普拉西坦水合物晶体及其制备方法 | |
| US4794197A (en) | All-cis-1,3,5-triamino-2,4,6,-cyclohexanetriol derivatives, their use, processes for their preparation and pharmaceutical preparations containing them | |
| US4739087A (en) | Antineoplastic platinum complexes | |
| US10717729B2 (en) | Thiamine-organic acid salt | |
| NZ237443A (en) | Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions | |
| US6271250B1 (en) | Metal Glycididaagolc, and preparation and uses thereof | |
| EP4574825A1 (en) | Crystal form of pyrazolopyrimidine ester compound and preparation method therefor | |
| WO2024234619A1 (zh) | 一种化合物的晶型、药物组合物及用途 | |
| CS269719B1 (en) | Platinum cytostatic | |
| JPH07508495A (ja) | オキシテトラサイクリンの精製方法および中間体 | |
| CN111228276B (zh) | 一种具有抗菌活性的溴代草酰胺双核铜配合物及其组合物 | |
| EA017521B1 (ru) | Комплексное соединение платины и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040706 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040716 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100723 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100723 Year of fee payment: 6 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100723 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |